Vaccine Maitri (Hindi: वैक्सीन मित्र, “vaccine friend”) was a diplomatic initiative launched by the Government of India in early 2021 to supply COVID‑19 vaccines to other countries, primarily those in the South Asian region and the broader Global South. The program was administered by the Ministry of External Affairs in coordination with the Ministry of Health and Family Welfare, and it operated alongside commercial export arrangements for Indian‑manufactured vaccines.
Objectives
The stated objectives of Vaccine Maitri were to:
- Provide humanitarian assistance to nations facing vaccine shortages.
- Enhance India’s vaccine diplomacy and strengthen bilateral relations.
- Contribute to the global effort to control the COVID‑19 pandemic.
Vaccines Distributed
The programme distributed two vaccines that were produced in India:
- Covishield – the Indian‑manufactured version of the Oxford–AstraZeneca vaccine, produced by the Serum Institute of India (SII).
- Covaxin – an inactivated virus vaccine developed by Bharat Biotech in partnership with the Indian Council of Medical Research (ICMR).
Both vaccines were supplied either as outright donations (grants) or under commercial agreements, depending on the recipient country’s request and the terms negotiated.
Timeline and Scale
| Date (approx.) | Cumulative doses supplied* | Notable recipient regions/countries |
|---|---|---|
| March 2021 | ~10 million | Nepal, Bhutan, Maldives, Afghanistan |
| July 2021 | ~50 million | Africa (e.g., Zambia, Tanzania, Benin), Caribbean (e.g., Haiti), Central America (e.g., Honduras) |
| October 2021 | ~162 million | Expanded to additional African, Asian, and Latin American nations |
| January 2022 | ~202 million | Continued deliveries to existing partners and new recipients such as Madagascar and the Republic of Congo |
*Figures represent the sum of donated and commercially exported doses reported by the Ministry of External Affairs and the respective vaccine manufacturers. Exact numbers are subject to change as updates are released.
Key Recipients
- South Asia: Nepal, Bhutan, Maldives, Afghanistan.
- Southeast Asia: Vietnam, Indonesia (limited).
- Africa: Zambia, Tanzania, Benin, Madagascar, Republic of Congo, Botswana, Seychelles.
- Latin America and the Caribbean: Haiti, Honduras, Dominican Republic, Jamaica, Belize.
Operational Aspects
- Logistics: Doses were shipped using a combination of air freight and maritime transport, often coordinated with the Indian Armed Forces and diplomatic missions.
- Financing: While many shipments were donated, some were sold at cost or under commercial contracts to offset production expenses.
- Regulatory Clearance: Recipient countries received the vaccines under emergency use authorizations or WHO Emergency Use Listing (EUL) where applicable.
Challenges and Adjustments
During the severe surge of COVID‑19 cases in India in April–May 2021, domestic demand for vaccines rose sharply, leading the government to temporarily pause or scale back some overseas shipments to prioritize internal vaccination campaigns. The pause was gradually lifted as domestic production capacity expanded and the domestic surge subsided.
Impact and Reception
International observers and recipient governments generally welcomed the initiative as a demonstration of solidarity. The programme was cited in several diplomatic statements as evidence of India’s commitment to global health security. However, some analysts noted that the scale of the programme was constrained by India’s own production capacity and domestic public‑health needs.
Current Status
As of mid‑2022, Vaccine Maitri continued on a reduced scale, focusing on bilateral agreements and targeted assistance rather than large‑volume bulk shipments. The initiative’s activities have been integrated into broader “vaccine diplomacy” efforts undertaken by India in collaboration with multilateral mechanisms such as the COVAX Facility.
References
- Ministry of External Affairs, Government of India – press releases on Vaccine Maitri (2021‑2022).
- Serum Institute of India – annual reports on Covishield production and export.
- Bharat Biotech – statements on Covaxin supply commitments.
- World Health Organization – data on vaccine shipments to participating countries.
Note: All quantitative data reflect publicly released figures and may be updated as additional official reports become available.